ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the ... Rituximab; SLL: Small lymphocytic lymphoma; VOD: Veno-occlusive disease. Y-A Chu and W Polson are employees ...

A Phase I study included 13 patients with a variety of relapsed B-cell NHL (five follicular, three mantle cell, three DLBCL, two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]).

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic ...

non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid ...

Tecartus will launch with a $373,000 list price, around the same as Gilead/Kite's first CAR-T – non-Hodgkin’s lymphoma therapy ... for diffuse large B cell lymphoma (DLBCL) and – they ...

Marker Therapeutics to receive two grants from NIH Small Business Innovation Research ... responses among post-CAR-T diffuse large B-cell lymphoma patients treated with neldaleucel by Q4, and ...

The answer turned out to be a cutting-edge treatment that few Americans know about, according to Roswell Park Comprehensive ...

Explore the complexities of SIBO, its impact on gut health, and evolving diagnostic methods for this often-misunderstood ...